Navigation Links
Predicting ovarian cancer survival through tumor-attacking immune cells
Date:12/4/2013

SEATTLE One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult until now.

Scientists at Fred Hutchinson Cancer Research Center have developed a new method for counting a special class of cancer-fighting cells called tumor-infiltrating T lymphocytes, or TILs reliably, quickly and cheaply in patients with early stage and advanced ovarian cancer. They describe their findings online Dec. 4 in Science Translational Medicine.

Such technology, a DNA-amplification technique, has the potential to predict treatment response, cancer recurrence and disease-free survival earlier and more effectively than any current method, according to lead researcher and cancer geneticist Jason H. Bielas, Ph.D., an associate member of the Human Biology and Public Health Sciences divisions at Fred Hutch.

"Our experiments demonstrate an association between higher TIL counts and improved survival among women with ovarian cancer, and are consistent with prior observations that the immune response against ovarian cancer is a meaningful and independent prognostic factor," said Bielas, who was also the paper's corresponding and senior author.

"While variations in the measurement and characterization of TILs have limited their clinical utility as biomarkers of survival, our results highlight the significant translational potential of a robust, standardized, DNA-based assay to assess TILs in a variety of cancer types, including ovarian," he said.

Fred Hutch researchers developed the digital assay to count TILs, determine their frequency and develop a grouping system to determine their "clonality," a measure of the tumor's T-cell population.

In developing the test, Bielas and his team leveraged a technology co-created by first author Harlan S. Robins, Ph.D., a computational biologist and associate member of the Public Health Sciences and Human Biology divisions at Fred Hutch. They devised a way to easily screen T cells by capturing the genetic information of unique proteins these cells carry on their surface. Fred Hutch licensed the technology to Adaptive Biotechnologies, a company Robins co-founded.

In the present study, Robins, Bielas and colleagues tested this novel technique, called "QuanTILfy," on tumor samples from 30 ovarian cancer patients with known survival outcomes ranging from one to 22 months. They looked at the levels of TILs in their tumors and compared those levels to the women's survival. They found that higher TIL numbers correlated with better survival. For example, the percentage of TILs was approximately threefold higher on average for patients with a survival rate of more than five years as compared to patients with a survival rate of less than two years.

"Now that we have the sensitivity and ability to reproducibly count TILs in tumors, we may be able to stratify and more effectively treat patients based on tumor TIL count," Bielas said.


'/>"/>

Contact: Kristen Woodward
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Study examines BI-RADS and MRI in predicting breast cancer
2. Predicting post-traumatic stress disorder before it happens
3. A new model for predicting recovery after spinal cord injury
4. Study uncovers simple way of predicting severe pain following breast cancer surgery
5. Researchers develop non-invasive technique for predicting patients response to chemotherapy
6. Predicting, preventing, and controlling pandemics: Making the case for a strategic action plan
7. Valuable tool for predicting pain genes in people
8. Combining diagnostic tests more accurate at predicting Alzheimers
9. Predicting risk of arrhythmias and sudden cardiac death: Theres a computer model for that
10. Predicting hotspots for future flu outbreaks
11. Medtronic Infuse Bone Graft Lawsuits: Bernstein Liebhard LLP Notes New Report Predicting Hundreds of Medtronic Infuse Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... from offices headquartered in Jefferson County, is announcing the launch of a charity ... , The number of homeless women and children in Birmingham has grown steadily ...
(Date:12/8/2016)... St. Louis, MS (PRWEB) , ... December 08, 2016 , ... ... offices that serve commercial and residential clients in and around the Hancock County area, ... support for the Hancock County Food Pantry. , The Hancock County Food Pantry has ...
(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
(Date:12/7/2016)... ... ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than 30 ... sealed, LED luminaire that meets the needs of everyone in the patient room by ... , A 2’ x 4’ model features four modes: reading, ambient, standard and high ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Hanson Research, an innovative leader in the ... testing instruments for the pharmaceutical industry, announced today ... ("Teledyne"). The move is designed to deepen investments ... as well as expand resources for further market ... services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
(Date:12/8/2016)... Dec. 8, 2016 Augmedix, the nation,s ... it has closed a $23 million strategic round ... OrbiMed. The company seeks to rehumanize the physician ... on mandated EHR documentation. The Augmedix core offering ... frees doctors from 3 hours of mandated charting ...
(Date:12/8/2016)... N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. (NYSE: ... of $18,800,000, or $0.45 per diluted share, on a 22.1% ... quarter ended October 31, 2016. This compares with net income ... $153,779,000 for the first quarter ended October 31, 2015. ... quarter ended October 31, 2016 to $21,323,000, or $0.51 per ...
Breaking Medicine Technology: